Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant.

Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK.

Ther Adv Psychopharmacol. 2016 Apr;6(2):99-144. doi: 10.1177/2045125316629071. Epub 2016 Feb 18. Review.

2.

Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy.

Zorumski CF, Nagele P, Mennerick S, Conway CR.

Front Psychiatry. 2015 Dec 9;6:172. doi: 10.3389/fpsyt.2015.00172. eCollection 2015. Review.

3.

Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial.

Wang Z, Xu X, Tan Q, Li K, Ma C, Xie S, Gao C, Wang G, Li H.

Shanghai Arch Psychiatry. 2015 Aug 25;27(4):228-36. doi: 10.11919/j.issn.1002-0829.215064.

4.

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder.

Zhang XF, Wu L, Wan DJ, Liu RZ, Dong Z, Chen M, Yu SY.

Neuropsychiatr Dis Treat. 2015 Aug 4;11:1957-65. doi: 10.2147/NDT.S87968. eCollection 2015.

5.

Pharmacological approaches to the challenge of treatment-resistant depression.

Ionescu DF, Rosenbaum JF, Alpert JE.

Dialogues Clin Neurosci. 2015 Jun;17(2):111-26. Review.

6.

Prevalence and prescription of antidepressants in depression with somatic comorbidity in Asia: the Research on East Asian Psychotropic Prescription Patterns study.

Chen C, Si TM, Xiang YT, Ungvari GS, Wang CY, He YL, Kua EH, Fujii S, Sim K, Trivedi JK, Chung EK, Udomratn P, Chee KY, Sartorius N, Tan CH, Shinfuku N.

Chin Med J (Engl). 2015 Apr 5;128(7):853-8. doi: 10.4103/0366-6999.154272.

7.

Toward an online cognitive and emotional battery to predict treatment remission in depression.

Gordon E, Rush AJ, Palmer DM, Braund TA, Rekshan W.

Neuropsychiatr Dis Treat. 2015 Feb 26;11:517-31. doi: 10.2147/NDT.S75975. eCollection 2015.

8.

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Mathews M, Gommoll C, Chen D, Nunez R, Khan A.

Int Clin Psychopharmacol. 2015 Mar;30(2):67-74. doi: 10.1097/YIC.0000000000000057.

9.

Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial.

Hollon SD, DeRubeis RJ, Fawcett J, Amsterdam JD, Shelton RC, Zajecka J, Young PR, Gallop R.

JAMA Psychiatry. 2014 Oct;71(10):1157-64. doi: 10.1001/jamapsychiatry.2014.1054.

10.
11.

Contemporary concepts in the pharmacotherapy of depression in older people.

Rojas-Fernandez C, Mikhail M.

Can Pharm J (Ott). 2012 May;145(3):128-135.e2. doi: 10.3821/145.3.cpj128.

12.

Role of repetitive transcranial magnetic stimulation in maintenance treatment of resistant depression.

Chatterjee B, Kumar N, Jha S.

Indian J Psychol Med. 2012 Jul;34(3):286-9. doi: 10.4103/0253-7176.106039.

13.

Antidepressant use and new-onset diabetes: a systematic review and meta-analysis.

Bhattacharjee S, Bhattacharya R, Kelley GA, Sambamoorthi U.

Diabetes Metab Res Rev. 2013 May;29(4):273-84. doi: 10.1002/dmrr.2393. Review.

14.

Multi-modality: a new approach for the treatment of major depressive disorder.

Richelson E.

Int J Neuropsychopharmacol. 2013 Jan 30:1-10. [Epub ahead of print]

15.

Pharmacological strategies in the prevention of relapse after electroconvulsive therapy.

Prudic J, Haskett RF, McCall WV, Isenberg K, Cooper T, Rosenquist PB, Mulsant BH, Sackeim HA.

J ECT. 2013 Mar;29(1):3-12. doi: 10.1097/YCT.0b013e31826ea8c4.

16.

Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data.

Ellis AR, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Stürmer T.

Pharmacoepidemiol Drug Saf. 2013 Feb;22(2):138-44. doi: 10.1002/pds.3396. Epub 2012 Dec 28.

17.

National trends in prayer use as a coping mechanism for depression: changes from 2002 to 2007.

Wachholtz AB, Sambamthoori U.

J Relig Health. 2013 Dec;52(4):1356-68. doi: 10.1007/s10943-012-9649-y.

18.

Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response.

Hodgson K, Mufti SJ, Uher R, McGuffin P.

Genome Med. 2012 Jun 27;4(6):52. doi: 10.1186/gm351.

19.

The prognostic significance of subsyndromal symptoms emerging after remission of late-life depression.

Kiosses DN, Alexopoulos GS.

Psychol Med. 2013 Feb;43(2):341-50. doi: 10.1017/S0033291712000967. Epub 2012 May 21.

20.

Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.

Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ.

Arch Gen Psychiatry. 2012 Jun;69(6):580-7. doi: 10.1001/archgenpsychiatry.2011.2048. Erratum in: Arch Gen Psychiatry.2013 Aug;70(8):881.

Items per page

Supplemental Content

Write to the Help Desk